Effects of aspirin, nimesulide, and SC-560 on vasopressin-induced contraction of human gastroepiploic artery and saphenous vein

Critical Care Medicine

Volumn 36, Issue 1, 2008, Pages 193-197

  Aldasoro, Martin ^a   Mauricio, Maria D ^a   Serna, Eva ^a   Cortina, Belen ^a   Segarra, Gloria ^a   Medina, Pascual ^a   Vila, José M ^a   Flor, Blas ^b   Lluch, Salvador ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cyclooxygenase inhibition; Human gastroepiploic artery; Human saphenous vein; Vasopressin V1 receptor

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR ANTAGONIST; [[1 (BETA MERCAPTO BETA, BETA CYCLOPENTAMETHYLENEPROPIONIC ACID) 2 (O METHYL)TYROSINE, 8 ARGININE]VASOPRESSIN];

ADULT; AGED; ARTERY CONSTRICTION; ARTICLE; CONCENTRATION RESPONSE; CORONARY ARTERY BYPASS SURGERY; DRUG MECHANISM; FEMALE; GASTRECTOMY; GASTROEPIPLOIC ARTERY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; VENOCONSTRICTION;

EID: 37549006772     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000292155.06797.62     Document Type: Article

References (31)

1. Aldasoro M, Medina P, Vila JM, et al: Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg 1997; 25:696-703
2. Wei W, Yang CQ, Furnary A, et al: Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery. J Thorac Cardiovasc Surg 2005; 129:33-40
3. Medina P, Noguera I, Aldasoro M, et al: Enhancement by vasopressin of adrenergic responses in human mesenteric arteries. Am J Physiol 1997; 272:H1087-H1093
4. Medina P, Acuña A, Martínez-León JB, et al: Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein. Circulation 1998; 97:865-870
5. Share L: Role of vasopressin in cardiovascular regulation. Physiol Rev 1988; 68:1248-1284
6. Krismer AC, Wenzel V, Stadlbauer KH, et al: Vasopressin during cardiopulmonary resuscitation: A progress report. Crit Care Med 2004; 32:S432-S435
7. Barrett LK, Singer M, Clapp LH: Vasopressin: Mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:33-40
8. Dunser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
9. Dunser MW, Mayr AJ, Ulmer H, et al: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 2001; 93:7-13
10. 2+] in the neonatal rat cardiomyocyte: Evidence for V1 subtype receptors. Circ Res 1991; 69:239-245
11. Rouleau JL, Packer M, Moye L, et al: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994; 24:583-591
12. Goldsmith SR, Gheorghiade M: Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791
13. Arai Y, Fujimori A, Sudoh K, et al: Vasopressin receptor antagonists: Potential indications and clinical results. Curr Opin Pharmacol 2007; 7:124-129
14. Pym J, Brown PM, Charrette EJ, et al: Gastroepiploic-coronary anastomosis: A viable alternative bypass graft. J Thorac Cardiovasc Surg 1987; 94:256-259
15. Favaloro RG: Clinical application of direct myocardial revascularization by saphenous vein graft technique. Heart Lung 1973; 2:45-46
16. Buikema H, Grandjean JG, van den Broek S, et al: Differences in vasomotor control between human gastroepiploic and left internal mammary artery. Circulation 1992; 86:II205-II209
17. Catella-Lawson F: Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57:S5-S7
18. Caughey GE, Cleland LG, Penglis PS, et al: Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167:2831-2838
19. McAdam BF, Catella-Lawson F, Mardini IA, et al: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Nat Acad Sci U S A 1999; 96:272-277
20. Vanner S, Jiang MM, Brooks VL, et al: Characterization of vasopressin actions in isolated submucosal arterioles of the intestinal microcirculation. Circ Res 1990; 67:1017-1026
21. Li M, Stallone JN: Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function. Am J Physiol Heart Circ Physiol 2005; 289:H1542-H1550
22. Altura BM, Altura BT: Vascular smooth muscle and neurohypophyseal hormones. Fed Proc 1977; 36:1853-1860
23. García-Villalón AL, García JL, Fernandez N, et al: Regional differences in the arterial response to vasopressin: Role of endothelial nitric oxide. Br J Pharmacol 1996; 118:1848-1854
24. Mangano DT: Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309-1317
25. Cheng Y, Austin SC, Rocca B, et al: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296:539-541
26. Egan KM, Lawson JA, Fries S, et al: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306:1954-1957
27. Philbin DM, Coggins CH, Wilson N, et al: Antidiuretic hormone levels during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1977; 73:145-148
28. Hupf H, Grimm D, Riegger GAJ, et al: Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84:365-370
29. Martínez MC, Vila JM, Aldasoro M, et al: Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Br J Pharmacol 1994; 113:419-424
30. Udelson JE, Smith WB, Hendrix GH, et al: Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417-2423
31. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595